Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kraft Heinz Co (KHC) vs Stryker Corporation (SYK) Price & Performance

Kraft Heinz CoTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Kraft Heinz Co vs Stryker Corporation — how do they compare? Kraft Heinz Co trades at $22.2 (market cap $26.66B), while Stryker Corporation trades at $277.29 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 4× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Stryker Corporation for 21 Days on average.

KHCSYK
Market Cap
$26.66B$106.24B
Volume
31,300,1092,982,001
Sector
Consumer StaplesHealth
52-Week High
$27.62$388.35
52-Week Low
$21.21$269.75
Typical Hold Time
129 Days21 Days
Enterprise Value
$42.98B$117.70B
Dividend Yield
7.12%1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kraft Heinz Co

Kraft Heinz (KHC) trades at $22.08, up 0.45% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with a low P/E of 13.04 and P/B of 0.74, but negative profitability metrics including a net income margin of -13.64% and ROE of -8.78% reflect challenges from a recent $5.85B net loss in 2025. The company maintains strong operating cash flow of $4.46B and a dividend yield near 6.5%, supported by ongoing brand reinvestment efforts.

The investment outlook is cautious; valuation discounts may attract value investors, but persistent volume declines and high debt pose significant risks. Analyst consensus is mixed with a $24.50 price target, yet only 11.43% recommend buying. Key catalysts include successful turnaround execution and new product launches, though competitive pressures and margin recovery remain critical hurdles for sustained shareholder value.

Stryker Corporation

Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.

The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KHC
100% Buy0% Sell
Avg holding period · 129 Days
SYK

No sentiment data available yet.

Top news

Latest headlines on both assets

About Kraft Heinz Co

In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.

Read more on KHC →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →